scholarly journals Rectal Cancer Patient with Complete Response to Neoadjuvant Chemoradiotherapy

2020 ◽  
Vol 26 (1) ◽  
pp. 29-32
Author(s):  
Seung-Gu Yeo
Keyword(s):  
Rectal Cancer ◽  
Cancer Patient ◽  
Rectal Cancer Patient ◽  
Neoadjuvant Chemoradiotherapy ◽  
Complete Response

scholarly journals Non-operative treatment outcome for rectal cancer patient with clinical complete response after neoadjuvant chemoradiotherapy

2019 ◽  
Vol 42 (8) ◽  
pp. 823-831 ◽  
Author(s):  
Seung-Seop Yeom ◽  
Soo Young Lee ◽  
Chang Hyun Kim ◽  
Young Jin Kim ◽  
Taek-Keun Nam ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Treatment Outcome ◽  
Cancer Patient ◽  
Operative Treatment ◽  
Rectal Cancer Patient ◽  
Neoadjuvant Chemoradiotherapy ◽  
Complete Response ◽  
Clinical Complete Response

scholarly journals Case Report of a Clinically Complete Response in a Rectal Cancer Patient after Chemoradiotherapy with a 2-year Watch and Wait Approach

2017 ◽  
Vol 42 (5) ◽  
pp. 835-840
Author(s):  
Matsuda Keiji ◽  
Ohno Kohei ◽  
Okada Yuka ◽  
Yagi Takahiro ◽  
Tsukamoto Mitsuo ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Case Report ◽  
Cancer Patient ◽  
Rectal Cancer Patient ◽  
Complete Response ◽  
Watch And Wait

scholarly journals Increasing serum miR-124-3p expression is associated with the high survival rate of a rectal cancer patient after neoadjuvant chemoradiotherapy

2019 ◽  
Vol 10 (2) ◽  
pp. 90-95
Author(s):  
Sri Nuryani Wahyuningrum ◽  
Christina Hari Nawangsih Priharsanti ◽  
Sofia Mubarika Haryana ◽  
Ahmad Ghozali
Keyword(s):  
Colorectal Cancer ◽  
Rectal Cancer ◽  
Cancer Patient ◽  
Patient Survival ◽  
Rectal Cancer Patient ◽  
Neoadjuvant Chemoradiotherapy ◽  
Health Science ◽  
High Survival ◽  
Science Journal ◽  
Qrt Pcr

Latar Belakang: Kanker kolorektal menempati urutan ketiga penyebab kanker di dunia, dengan prevalensi kanker rektum sebanyak 30% dari total kasus. Saat ini belum ada biomarker yang efektif untuk memprediksi respon pasien terhadap terapi yang diberikan. Beberapa penelitian menggunakan potensi miRNA sebagai biomarker untuk melihat respon terapi. Salah satunya yaitu MiR-124-3p berperan sebagai tumor supresor yang mengalami penurunan ekspresi pada berbagi jenis kanker. Tujuan dari penelitian ini adalah untuk meneliti ekspresi miR-124-3p dari pasien kanker rektum yang menerima nCRT, dan menganalisis hubungannya dengan kelangsungan hidup pasien dan parameter klinis lainnya. Metode: Penelitian ini melibatkan 15 orang pasien yang didiagnosis menderita kanker rektum lokal dan menjalani kemoradioterapi neoajuvan (radioterapi 45-50 Gy dengan fraksi 1,8-2 Gy selama 1-3 bulan, dan kemoterapi 5-fluororacil secara oral). Sampel penelitian berupa darah intravena sebanyak 5 ml diambil saat sebelum dan sesudah kemoradioterapi. Selanjutnya ekspresi miR-124-3p dianalisis menggunakan qRT-PCR dan dikalkulasi menggunakan metode Livak. Hasil: Terdapat hubungan signifikan antara peningkatan ekspresi miR-124-3p dengan sintasan hidup pasien (P=0,003; OR =30, 95% CI = 1,41 – 638,15), serta adanya peningkatan ekspresi miR-124-3p yang signifikan (P<0,041, fold change sebelum=1,14 ± 1,25; sesudah=2,4 ± 1,84) setelah dilakukan kemoradioterapi. Kesimpulan: Hasil ini mengindikasikan bahwa miR-124-3p berpotensi menjadi biomarker untuk memprediksi sintasan hidup pasien kanker rektum yang menerima kemoradioterapi. (Health Science Journal of Indonesia 2019;10(2):90-5) Kata kunci: kanker rektum, kemoradioterapi, miR-124-3p, sintasan hidup   Abstract Background: Colorectal cancer is the world’s third most prevalent cancer, which 30% of cases are rectal cancer. Today, the effective diagnostic marker to accurately predict clinical outcome patients response to therapy did not found yet. Several research studies have indicated that miRNA potential as a prognostic biomarker. MiR 124-3p plays as tumor suppressor that significantly down-regulated in some cancer and could radiosensitize human colorectal cancer cells. The aim of the study is to investigate the expression of miR-124-3p from rectal cancer patient who receive nCRT, and analyze its association with patient survival and others clinical parameters. Methods: This research involved 15 patients with histologically confirmed locally advanced rectal cancer (LARC) and received neoadjuvant chemotherapy/nCRT (radiotherapy 45-50 Gy with 1,8-2 Gy fractions over 1 to 3 months and chemotherapy 5-fluorouracil was administered orally). Patient blood (5 ml) were collected from peripheral venous before and after neoadjuvant chemoradiotherapy. miR-124-3p expression was performed using qRT-PCR and calculate using Livak method. Results: In this study, we found that increasing of miR-124 was significantly associate with high survival of rectal cancer patient (P = 0,003; OR =30, 95% CI = 1,41 – 638,15). Average of miR-124-3p expression increase significantly after nCRT (P<0,041, fold change before=1,14 ± 1,25; after=2,4 ± 1,84). Conclusion: Our finding suggests that miR-124-3p expression in blood serum was potential as biomarkers to predict rectal cancer patient survival after neoajduvant chemoradiotherapy. (Health Science Journal of Indonesia 2019;10(2):90-5) Keywords : rectal cancer, chemoradiotherapy, miR-124-3p, survival

Sign in / Sign up

Export Citation Format

Share Document